Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Geron, a developer of biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, has announced the pricing of an underwritten public offering of 7.25 million shares of its common stock.
Subscribe to our email newsletter
The offering is expected to close on February 19, 2009. On February 12, 2009, the last reported sales price of Geron common stock on the Nasdaq global market was $7.77.
UBS Investment Bank is acting as sole book-running manager for the offering. Lazard Capital Markets is acting as co-manager for this offering.
Geron intends to use the net proceeds from the offering for R&D, clinical trials and general corporate purposes.